高手术量机构并非总是低风险:在神经肿瘤外科中比较风险标化死亡率与机构手术量作为质量指标
该回顾性观察队列研究利用美国国家癌症数据库2009—2018年数据,纳入胶质母细胞瘤、垂体腺瘤和脑膜瘤手术成人患者。研究发现风险标化死亡率与机构手术量分类差异显著,基于风险标化死亡率的集中化模型在胶质母细胞瘤手术中比基于手术量的模型更有效且更高效。
要点
- 风险标化死亡率与机构手术量对胶质母细胞瘤、垂体腺瘤和脑膜瘤的分类存在显著差异。
- 胶质母细胞瘤手术中,基于风险标化死亡率的集中化模型平均需36例患者转院至低死亡率医院以预防1例术后30天死亡,而基于高手术量医院需46例。
- 黑人和西班牙裔患者、收入低于38000美元的患者及无保险患者更可能在高死亡率医院接受治疗。
核心结论
- 风险标化死亡率在预防胶质母细胞瘤术后早期死亡方面比传统的基于手术量的方法更有效且更高效,这些数据对未来神经肿瘤外科质量相关研究具有重要意义,并可能与医疗/保险支付、医院评估、医疗差异及医院间诊疗标准化相关。
研究设计与样本
- 回顾性观察队列研究,使用美国国家癌症数据库(来自美国1500多家机构的人群肿瘤学结局数据库),纳入2009—2018年诊断为胶质母细胞瘤、垂体腺瘤或脑膜瘤并接受手术的18岁及以上成人患者。
- 在训练集(2009—2013年)中计算各肿瘤组的风险标化死亡率五分位数和年手术量阈值,并将这些阈值应用于验证集(2014—2018年)。
- 比较基于机构手术量与基于风险标化死亡率的医院集中化模型的有效性和效率,并评估两种系统的重叠情况;同时进行诊疗模式分析以探索在表现更好的治疗机构接受治疗的社会经济预测因素。
主要发现
- 2014—2018年共有37838例脑膜瘤、21189例垂体腺瘤和30788例胶质母细胞瘤患者接受手术治疗。
- 在所有肿瘤类型中,风险标化死亡率与机构手术量分类方案之间存在显著差异。
- 在基于风险标化死亡率的集中化模型中,平均需要36例胶质母细胞瘤手术患者转院至低死亡率医院以预防1例术后30天死亡,而需要46例患者转院至高手术量医院。
- 对于垂体腺瘤和脑膜瘤,两种指标在通过集中化诊疗降低手术死亡率方面均效率低下。
- 胶质母细胞瘤患者的总生存期在风险标化死亡率分类方案中建模更优。
关键数值与推荐
- 胶质母细胞瘤手术中,基于风险标化死亡率的集中化模型平均需36例患者转院至低死亡率医院以预防1例术后30天死亡,而基于高手术量医院需46例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Risk-standardized mortality rates (RSMRs) have recently been shown to outperform facility case volume as a proxy for surgical quality in lung and gastrointestinal cancer. The aim of this study was to investigate RSMR as a surgical quality metric in primary CNS cancer. METHODS: This retrospective observational cohort study used data from the National Cancer Database, a population-based oncology outcomes database sourced from more than 1500 institutions in the United States, and included adult patients 18 years of age and older who were diagnosed with glioblastoma, pituitary adenoma, or meningioma and were treated with surgery. For each group, RSMR quintiles and annual volume were calculated in a training set (2009-2013) and these thresholds were applied to the validation set (2014-2018). In this paper, the authors compared the effectiveness and efficiency of facility volume-based versus RSMR-based hospital centralization models and evaluated the overlap between the two systems. A patterns-of-care analysis was also performed to explore socioeconomic predictors of being treated at better-performing treating facilities. RESULTS: A total of 37,838 meningioma, 21,189 pituitary adenoma, and 30,788 glioblastoma patients were surgically treated from 2014 to 2018. There were substantial differences between RSMR and facility volume classification schemes among all tumor types. In an RSMR-based centralization model, an average of 36 patients undergoing glioblastoma surgery would need to relocate to a low-mortality hospital to prevent one 30-day mortality following surgery, whereas 46 would need to relocate to a high-volume hospital. For pituitary adenoma and meningioma, both metrics were inefficient in centralizing care to reduce surgical mortality. Additionally, overall survival for glioblastoma patients was better modeled in an RSMR classification scheme. Analyses to investigate the impact of care disparities found that Black and Hispanic patients, patients earning less than $38,000, and uninsured patients were more likely to be treated at high-mortality hospitals. CONCLUSIONS: RSMR is more effective and efficient than a traditional volume-based approach for preventing early postoperative death in glioblastoma surgery. These data have important implications for future quality-related studies in neurosurgical oncology and may be relevant for healthcare/insurance payments, hospital evaluation assessments, healthcare disparities, and the standardization of care across hospitals.
引用
- Chalif EJ, Young JS, Villa GR, et al. High-volume facilities are not always low risk: comparing risk-standardized mortality rates versus facility volume as quality measures in surgical neuro-oncology. J Neurosurg. 2023. PMID: 37410629. doi:10.3171/2023.5.JNS222913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。